Chief Executive Officer

Rob Lin serves as the Chief Executive Officer of Avista Therapeutics. He was the Founding CEO of BlueSphere Bio and is currently on the board of directors of BlueSphere Bio, Code Biotherapeutics, Avista Therapeutics, and VegaVect, Inc. Before his tenure as CEO at Avista TX, Dr. Lin led the finance and strategy team for the Global Health Program at the Bill & Melinda Gates Foundation. His previous experiences also include stints at Millennium Pharmaceuticals (now Takeda Oncology) and Dean and Company as a strategy consultant. Dr. Lin earned a PhD in Genetics and an MMSc at Harvard University, as well as an MS in Chemical Engineering and a BS in Biological Sciences from Stanford University. He is a CFA Charterholder and previous Term Member of the Council on Foreign Relations (CFR).